Síndrome antifosfolípido: generalidades y diagnóstico

  • Magally Escobar Martínez Universidad Antonio Nariño
Palabras clave: síndrome antifosfolípido, anticuerpos antifosfolípidos, inhibidor de coagulación del lupus, anticuerpos anticardiolipina, beta 2 glicoproteína I.

Resumen

El síndrome antifosfolípido ha sido un tema de investigación continua en diferentes áreas de la medicina. El diagnóstico clínico y de laboratorio se realiza teniendo en cuenta los consensos internacionales de Sapporo (1999) y Sydney (2006), los cuales dan las pautas para identificar y caracterizar el síndrome antifosfolípido. El objetivo primordial de este artículo, es describir los avances científicos en el estudio del síndrome antifosfolípido, los criterios actuales de clasificación, el papel de los anticuerpos anticardiolipina, anti β2 glicoproteína I y el anticoagulante lúpico, así como los mecanismos patogénicos e inmunológicos en los que están involucrados estos anticuerpos. También se describen algunas de las manifestaciones clínicas relacionadas y los procedimientos diagnósticos utilizados actualmente para su identificación.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Magally Escobar Martínez, Universidad Antonio Nariño

Bacterióloga y Laboratorista Clínica, MSc Inmunología. Candidata a Doctor en Inmunología, Docente Investigadora, Facultad de Medicina, Universidad Antonio Nariño. Bogotá, Colombia.

Referencias bibliográficas

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-218.

https://doi.org/10.1177/0961203310395803

Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157: 47-58.

https://doi.org/10.1111/j.1365-2141.2012.09037.x

Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368: 1033-1044.

https://doi.org/10.1056/NEJMra1112830

Lockshin MD. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis 2008; 66: 195-197.

Alonso Santor JE, Inglada Galiana L, Perez Paredes G. Síndrome antifosfolípido: estado actual. An Med Interna 2007; 24: 242-248.

https://doi.org/10.4321/S0212-71992007000500009

Lockshin MD, Sammaritano LR. Antiphospholipid antibodies and fetal loss. N Engl J Med 1992; 326: 951-952; author reply 953-954.

https://doi.org/10.1056/NEJM199204023261411

Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 2011; 10: 609-616.

https://doi.org/10.1016/j.autrev.2011.04.011

Aron AL, Gharavi AE, Shoenfeld Y. Mechanisms of action of antiphospholipid antibodies in the antiphospholipid syndrome. Int Arch Allergy Immunol 1995; 106: 8-12.

https://doi.org/10.1159/000236883

Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus 2008; 17: 405-411.

https://doi.org/10.1177/0961203308090025

Mackworth-Young CG. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 2004; 136: 393-401.

https://doi.org/10.1111/j.1365-2249.2004.02497.x

Dostal-Johnson D, Rote NS, Branch DW. IgG1 and IgG2 are the predominant subclasses of antiphospholipid antibody in women with the lupus anticoagulant. Clin Immunol Immunopathol 1990; 54: 309-319.

https://doi.org/10.1016/0090-1229(90)90092-5

Steinkasserer A, Barlow PN, Willis AC, Kertesz Z, Campbell ID, Sim RB, et al. Activity, disulphide mapping and structural modelling of the fifth domain of human beta 2-glycoprotein I. FEBS Lett 1992; 313: 193-197.

https://doi.org/10.1016/0014-5793(92)81442-O

Cheng HM. Apoptotic antigens, B2-glycoprotein I, and antiphospholipid autoantibodies. Blood 1996; 88: 4396.

https://doi.org/10.1182/blood.V88.11.4396a.4396a

Hunt JE, Krilis SA. Antiphospholipid antibodies, beta 2-glycoprotein I and thrombosis. Lupus 1993; 2: 285-287.

https://doi.org/10.1177/096120339300200501

Matsuura E, Igarashi M, Igarashi Y, Nagae H, Ichikawa K, Yasuda T, et al. Molecular definition of human beta 2-glycoprotein I (beta 2-GPI) by cDNA cloning and inter-species differences of beta 2-GPI in alternation of anticardiolipin binding. Int Immunol 1991; 3: 1217-1221.

https://doi.org/10.1093/intimm/3.12.1217

Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-715.

https://doi.org/10.1046/j.1365-2141.2000.02069.x

Pierangeli SS, Harris EN, Davis SA, DeLorenzo G. Beta 2-glycoprotein 1 (beta 2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992; 82: 565-570.

https://doi.org/10.1111/j.1365-2141.1992.tb06468.x

Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 90: 29-37.

https://doi.org/10.1161/hh0102.102795

Asherson RA, Hughes GR. Primary antiphospholipid syndrome. Am J Med 1993; 94: 345-346.

https://doi.org/10.1016/0002-9343(93)90072-W

Cheng HM, Yap CG. Natural beta 2-glycoprotein I-independent anticardiolipin autoantibodies are not age-related. Stroke 1996; 27: 1007-1008.

Rote NS, Dostal-Johnson D, Branch DW. Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol 1990; 163: 575-584.

https://doi.org/10.1016/0002-9378(90)91201-M

Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.

https://doi.org/10.1111/j.1538-7836.2006.01753.x

Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994; 152: 3685-3692.

Manfredi AA, Rovere P, Heltai S, Galati G, Nebbia G, Tincani A, et al. Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum 1998; 41: 215-223.

https://doi.org/10.1002/1529-0131(199802)41:2<215::AID-ART5>3.0.CO;2-X

Chen PP, Giles I. Antibodies to serine proteases in the antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 45-52.

https://doi.org/10.1007/s11926-009-0072-7

Merrill JT. Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus. Lupus 2004; 13: 869-876.

https://doi.org/10.1191/0961203304lu2026oa

Salle V, Maziere JC, Smail A, Cevallos R, Maziere C, Fuentes V, et al. Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome. J Clin Immunol 2008; 28: 291-297.

https://doi.org/10.1007/s10875-008-9188-1

Andree HA, Stuart MC, Hermens WT, Reutelingsperger CP, Hemker HC, Frederik PM, et al. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 1992; 267: 17907-17912.

Hoxha A, Ruffatti A, Tonello M, Bontadi A, Salvan E, Banzato A, et al. Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome. Lupus 2012; 21: 787-789.

https://doi.org/10.1177/0961203312441983

Sanmarco M, Boffa MC. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Lupus 2009; 18: 920-923.

https://doi.org/10.1177/0961203309106920

Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-365.

https://doi.org/10.1097/00005792-198911000-00003

Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.

https://doi.org/10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001; 185: 748-753.

https://doi.org/10.1067/mob.2001.117659

Plouffe L, Jr., White EW, Tho SP, Sweet CS, Layman LC, Whitman GF, et al. Etiologic factors of recurrent abortion and subsequent reproductive performance of couples: have we made any progress in the past 10 years? Am J Obstet Gynecol 1992; 167: 313-320; discussion 320-311.

https://doi.org/10.1016/S0002-9378(11)91407-0

Stirrat GM. Recurrent miscarriage. II: Clinical associations, causes, and management. Lancet 1990; 336: 728-733.

https://doi.org/10.1016/0140-6736(90)92215-4

Tincani A, Rebaioli CB, Frassi M, Taglietti M, Gorla R, Cavazzana I, et al. Pregnancy and autoimmunity: maternal treatment and maternal disease influence on pregnancy outcome. Autoimmun Rev 2005; 4: 423-428.

https://doi.org/10.1016/j.autrev.2005.03.001

Kutteh WH, Lyda EC, Abraham SM, Wacholtz MC. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. Fertil Steril 1993; 60: 449-455.

https://doi.org/10.1016/S0015-0282(16)56159-7

Lubbe WF, Pattison N, Liggins GC. Antiphospholipid antibodies and pregnancy. N Engl J Med 1985; 313: 1350-1351.

https://doi.org/10.1056/NEJM198511213132110

Mackworth-Young C. Antiphospholipid antibodies: more than just a disease marker? Immunol Today 1990; 11: 60-65.

https://doi.org/10.1016/0167-5699(90)90020-A

Diez-Ewald M. Anticuerpos antifosfolípidos. Revisión. Invest Clin 1993; 34: 143-158.

Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102: 2717-2723.

https://doi.org/10.1182/blood-2002-11-3334

Reber G, de Moerloose P. Anti-beta2-glycoprotein I antibodies--when and how should they be measured? Thromb Res 2004; 114: 527-531.

https://doi.org/10.1016/j.thromres.2004.06.034

Gharavi AE, Pierangeli SS, Levy RA, Harris EN. Mechanisms of pregnancy loss in antiphospholipid syndrome. Clin Obstet Gynecol 2001; 44: 11-19.

https://doi.org/10.1097/00003081-200103000-00003

Hanly JG, Smith SA, Anderson D. Inhibition of annexin V binding to cardiolipin and thrombin generation in an unselected population with venous thrombosis. J Rheumatol 2003; 30: 1990-1993.

Rand JH, Wu XX, Andree HA, Lockwood CJ, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N Engl J Med 1997; 337: 154-160.

https://doi.org/10.1056/NEJM199707173370303

Rand JH, Wu XX, Guller S, Scher J, Andree HA, Lockwood CJ. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi. Am J Obstet Gynecol 1997; 177: 918-923.

https://doi.org/10.1016/S0002-9378(97)70294-1

Ornoy A, Yacobi S, Matalon ST, Blank M, Blumenfeld Z, Miller RK, et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 2003; 12: 573-578.

https://doi.org/10.1191/0961203303lu405oa

Diogenes MJ, Diogenes PC, de Morais Carneiro RM, Neto CC, Duarte FB, Holanda RR. Cutaneous manifestations associated with antiphospholipid antibodies. Int J Dermatol 2004; 43: 632-637.

https://doi.org/10.1111/j.1365-4632.2004.01939.x

Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36: 970-982.

https://doi.org/10.1016/S0190-9622(97)80283-6

Daugas E, Nochy D, Huong DL, Duhaut P, Beaufils H, Caudwell V, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13: 42-52.

Nochy D, Daugas E, Hill G, Grunfeld JP. Antiphospholipid syndrome nephropathy. J Nephrol 2002; 15: 446-461.

Tektonidou MG, Sotsiou F, Nakopoulou L, Vlachoyiannopoulos PG, Moutsopoulos HM. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004; 50: 2569-2579.

https://doi.org/10.1002/art.20433

Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005; 20: 105-112.

https://doi.org/10.1007/s11239-005-3204-6

Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501-507.

https://doi.org/10.1016/j.thromres.2004.06.026

Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 735-741.

https://doi.org/10.1002/1529-0131(199904)42:4<735::AID-ANR17>3.0.CO;2-L

Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002; 11: 736-743.

https://doi.org/10.1191/0961203302lu255oa

Chalem P. Síndrome de anticuerpos antifosfolípidos: manifestaciones en el sistema nervioso central. Asociación Colombiana de Neurología. http://www.acnweb.org/guia/g3cap6.pdf. Consultado en julio de 2013.

Brey RL. Antiphospholipid antibodies and ischemic stroke. Heart Dis Stroke 1992; 1: 379-382.

Brey RL, Coull BM. Antiphospholipid antibodies: origin, specificity, and mechanism of action. Stroke 1992; 23: I15-18.

Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997; 28: 2363-2369.

https://doi.org/10.1161/01.STR.28.12.2363

Coull BM, Levine SR, Brey RL. The role of antiphospholipid antibodies in stroke. Neurol Clin 1992; 10: 125-143.

https://doi.org/10.1016/S0733-8619(18)30237-8

Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10: 455-460.

Levine SR, Brey RL, Joseph CL, Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke 1992; 23: I29-32.

Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M, Turgut M, Keskin H, Nalcaci M, et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-1764.

https://doi.org/10.1182/blood.V98.6.1760

Macchi L, Rispal P, Clofent-Sanchez G, Pellegrin JL, Nurden P, Leng B, et al. Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia. Br J Haematol 1997; 98: 336-341.

https://doi.org/10.1046/j.1365-2141.1997.2243038.x

Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-541.

https://doi.org/10.1055/s-0038-1650316

Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, et al. International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 2012; 64: 1-10.

https://doi.org/10.1002/art.33349

Bertolaccini ML, Khamashta MA. Diagnosis of antiphospholipid syndrome. Expert Rev Hematol 2008; 1: 183-188.

https://doi.org/10.1586/17474086.1.2.183

Harris EN, Pierangeli SS, Gharavi AE. Diagnosis of the antiphospholipid syndrome: a proposal for use of laboratory tests. Lupus 1998; 7 Suppl 2: S144-148.

https://doi.org/10.1177/096120339800700232

Pierangeli SS, Stewart M, Silva LK, Harris EN. An antiphospholipid wet workshop: 7th International Symposium on Antiphospholipid Antibodies. J Rheumatol 1998; 25: 156-160.

Medina Y, Martínez JB, Matínez O, Rondón F, Restrepo JF, Iglesias A. Lupus y síndrome antifosfolípido en el embarazo. Acta Med Colomb 2005; 30: 50-58.

Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.

https://doi.org/10.1111/j.1538-7836.2009.03555.x

Derksen RH, de Groot PG. Tests for lupus anticoagulant revisited. Thromb Res 2004; 114: 521-526.

https://doi.org/10.1016/j.thromres.2004.06.009

Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 168: 1675-1682.

Cómo citar
1.
Escobar Martínez M. Síndrome antifosfolípido: generalidades y diagnóstico. Med. Lab. [Internet]. 1 de septiembre de 2013 [citado 22 de enero de 2022];19(9-10):451-64. Disponible en: https://medicinaylaboratorio.com/index.php/myl/article/view/242
Publicado
2013-09-01
Sección
Inmunología